#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5           |
| obligations may continue. See          |
| Instruction 1(b).                      |

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name an   | EN  | 2. Issuer Name and Ticker or Trading Symbol ENANTA PHARMACEUTICALS INC [ ENTA ] |                  |   |           |  |   |   |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title below)  Director Other (specify below) |  |  |                                       |   | wner  |  |   |  |   |
|--|---|---|------------------|---|-----------|--|---|---|--|---|--|--|---------------------------------------|---|---|--|---|--|---|
|  | `   | First) (<br>ARMACEUTICA<br>REET   | 04/              | 3. Date of Earliest Transaction (Month/Day/Year) 04/16/2018 |           |  |   |   |  |   |  |  | Sr. VP & Chief Medical Officer        |   |   |  |   |  |   |
| (Street) WATERT  | ATERTOWN MA 02472   |   |                  |   | ,   4. II | 4. If Amendment, Date of Original Filed (Month/Day/Year) |   |   |  |   |  |  |                                       | Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person     Form filed by More than One Reporting Person |   |  |   |  |   |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |   |   |                  |   |           |  |   |   |  |   |  |  |                                       |   |   |  |   |  |   |
| 1. Title of Security (Instr. 3) 2. Trans   |   |   |                  | 2. Transaction  |           |  | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |   | 3.<br>Transaction<br>Code (Instr.<br>8)                  |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 an |  |                                       | _   | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported |  | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) |  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |
|  |   |   |                  |   | ,         |  |   |   | Code   | v   | Amount   | (A) or<br>(D)  | Price                                 |   | Transac<br>(Instr. 3  | ction(s)   |   |  | (Instr. 4)  |
| Common Stock 04/16/201   |   |   |                  |   | )18       | .8   |   |   | М  |   | 2,955  | A  | \$43.4                                | \$43.46   |   | 10,225   |   | D  |   |
| Common Stock 04/16/201   |   |   |                  |   | )18       | 18   |   |   | S <sup>(1)</sup>   |   | 1,800  | D  | \$85.1141(2)                          |   | 8,425   |  |   | D  |   |
| Common Stock 04/16/201   |   |   |                  |   | )18       | .8   |   | S <sup>(1)</sup>                              |  | 2,425   | D  | \$85.9193(3)   |                                       | 6,000   |   |  | D   |  |   |
|  |   | 1   |                  |   | outs,     |  | , wa  | arrant  | s, opt   | tions   | , converti   | ble sec  | urities)                              | )   |   |  | _   |  |   |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                              | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year)  | Execut<br>if any | Execution Date, if any                                      |           | 4.<br>Transaction<br>Code (Instr.<br>8)                  |   | ivative curities quired or posed D) str. 3, 4 | 6. Date Exercisable and Expiration Date (Month/Day/Year) |   |  | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Securi<br>(Instr. 3 and 4) |                                       | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   |   | 9. Number<br>derivative<br>Securities<br>Beneficiall<br>Owned<br>Following<br>Reported<br>Transactio<br>(Instr. 4) | illy  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4)               |
|  |   |   |                  |   |           | v  | (A) (D)   |   | Date<br>Exercisable                                      |   | Expiration<br>Date   | Title  | Amoun<br>or<br>Number<br>of<br>Shares | r   |   |  |   |  |   |
| Stock<br>Option<br>(Right to<br>Buy)   | \$43.46   | 04/16/2018  |                  |   | M         |  |   | 2,955   | (4   | 4)  | 06/29/2025   | Common<br>Stock  | 2,955                                 | 5   | \$0   | 87,045   | 5   | D  |   |

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$84.55 to \$85.45, inclusive.
- 3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$85.47 to \$86.45, inclusive.
- 4. The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.

## Remarks:

/s/ Nathaniel S. Gardiner as attorney-in-fact

04/18/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.